Cyclopentolatum [INN-Latin]
Brand names,
Cyclopentolatum [INN-Latin]
Analogs
Cyclopentolatum [INN-Latin]
Brand Names Mixture
Cyclopentolatum [INN-Latin]
Chemical_Formula
C17H25NO3
Cyclopentolatum [INN-Latin]
RX_link
No information avaliable
Cyclopentolatum [INN-Latin]
fda sheet
Cyclopentolatum [INN-Latin]
msds (material safety sheet)
Cyclopentolatum [INN-Latin]
Synthesis Reference
No information avaliable
Cyclopentolatum [INN-Latin]
Molecular Weight
291.385 g/mol
Cyclopentolatum [INN-Latin]
Melting Point
139 oC (hydrochloride salt)
Cyclopentolatum [INN-Latin]
H2O Solubility
No information avaliable
Cyclopentolatum [INN-Latin]
State
Solid
Cyclopentolatum [INN-Latin]
LogP
3.124
Cyclopentolatum [INN-Latin]
Dosage Forms
Ophthalmic solution (eye drops)
Cyclopentolatum [INN-Latin]
Indication
Used mainly to produce mydriasis and cycloplegia for diagnostic purposes.
Cyclopentolatum [INN-Latin]
Pharmacology
Cyclopentolate is an anti-muscarinic in the same class as atropine and scopolamine. Cyclopentolate blocks the receptors in the muscles of the eye (muscarinic receptors). These receptors are involved controlling the pupil size and the shape of the lens. Cyclopentolate thus induces relaxation of the sphincter of the iris and the ciliary muscles. When applied topically to the eyes, it causes a rapid, intense cycloplegic and mydriatic effect that is maximal in 15 to 60 minutes; recovery usually occurs within 24 hours. The cycloplegic and mydriatic effects are slower in onset and longer in duration in patients who have dark pigmented irises.
Cyclopentolatum [INN-Latin]
Absorption
Absorbed following ophthalmic administration.
Cyclopentolatum [INN-Latin]
side effects and Toxicity
Oral LD50 in the rat is 4000 mg/kg and 960 mg/kg in the mouse. Symptoms of overdose include tachycardia, dizziness, dry mouth, behavioral disturbances, uncoordination and drowsiness.
Cyclopentolatum [INN-Latin]
Patient Information
No information avaliable
Cyclopentolatum [INN-Latin]
Organisms Affected
Humans and other mammals